MK-1167 for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 29 Feb 2024: Trial registered, NCT06285240
  2. 28 Mar 2024: Trial started, NCT06285240

The trials

NCT06285240: Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

State
Completed
Phase
Phase 1
People
28 taking part
Started
28 Mar 2024
Primary completion
23 Sep 2024
Arms
Panel A: MK-1167 + Donepezil 10mg QD, Panel B: MK-1167 6mg QD + Donepezil 10mg QD
Results
Posted on the registry
  1. 29 Feb 2024: Trial registered
  2. 28 Mar 2024: Trial started
  3. 23 Sep 2024: Trial completed
  4. 14 Oct 2025: Trial results posted

NCT06721156: A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

State
Stopped early
Phase
Phase 2
People
369 taking part
Started
16 Dec 2024
Primary completion
5 Jun 2026
Arms
MK-1167 3 mg, MK-1167 1 mg, MK-1167 0.3 mg
Results
None posted
  1. 6 Dec 2024: Trial registered
  2. 16 Dec 2024: Trial started
  3. 5 Jun 2026: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.